The future for the treatment of genotype 4 chronic hepatitis C

Liver International

Volumn 32, Issue SUPPL. 1, 2012, Pages 146-150

  Esmat, G ^a,b   El Raziky, M ^a   El Kassas, M ^b   Hassany, M ^b   Gamil, M E ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b National Hepatology and Tropical Medicine Research Institute NHTMRI   (Egypt)

Author keywords

Genotype 4; HCV; IL28B polymorphism; Interferon ribavirin

Indexed keywords

ALBINTERFERON ALPHA2B; ALISPORIVIR; BOCEPREVIR; CONSENSUS INTERFERON; INTERLEUKIN 28B; NITAZOXANIDE; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; SILIBININ; TELAPREVIR; UNCLASSIFIED DRUG; VITAMIN D;

CLINICAL TRIAL; DRUG DOSE COMPARISON; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NEUTROPENIA; NONHUMAN; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ALBUMINS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; SERINE PROTEINASE INHIBITORS; THIAZOLES; TIME FACTORS; VIRAL LOAD; VITAMIN D;

EID: 84855232740     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02704.x     Document Type: Review

References (41)

1. Dienstag JL, McHutchison JG. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-30.
2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 5 (5 Suppl. 1): S21-9.
3. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 884-92.
4. Ray SC, Arthur RR, Carella A, et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698-707.
5. Al Faleh FZ, Huraib S, Sbeih F, et al. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia. J Viral Hepat 1995; 2: 293-6.
6. Shobokshi OA, Serebour FE, Skakni L, et al. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999; 58: 44-8.
7. Koshy A, Madda JP, Marcellin P, et al. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol 2002; 35: 82-5.
8. Fretz C, Jeannel D, Stuyver L, et al. HCV infection in a rural population of the Central African Republic (CAR): evidence for three additional subtypes of genotype 4. J Med Virol 1995; 47: 435-7.
9. Oni AO, Harrison TJ. Genotypes of hepatitis C virus in Nigeria. J Med Virol 1996; 49: 178-86.
10. Sanchez Quijano A, Abad MA, Torronteras R, et al. Unexpected 10. high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol 1997; 27: 25-9.
11. Matera G, Lamberti A, Quirino A, et al. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis 2002; 42: 169-73.
12. Remy AJ, Verdier E, Perney P, et al. Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country. J Hepatol 1998; 29: 169.
13. NIH. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.
14. ®) in combination with ribavirin (RBV). Hepatology 2002; 2: 364A.
15. ®) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia. Hepatology 2003; 384 (Suppl. 1): 636A.
16. Alfaleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 568-74.
17. Esmat G, Abouzied AM, Abdel Aziz F, et al. Treatment with PEG-interferon alfa-2b (PEG-IFN) plus ribavirin compared to interferon alfa-2b (IFN alfa-2b)plus ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4. Hepatology 2002; 2: 364A.
18. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 1733-7.
19. Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 1250-62.
20. Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011; 31 (Suppl. 1): 45-52.
21. Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009; 49: 1838-46.
22. Yee HS, Currie SL, Tortorice K, et al. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. Dig Dis Sci 2011; 56: 2439-48.
23. Nelson D, Rustgi VK, Balan V, et al. Sustained virologic response with albinterferon alfa-2b plus ribavirin treatment in prior interferon therapy nonresponders [abstract 51]. Hepatology 2007; 464 Suppl. 1: 256A.
24. Mohamed K. Ashour, Maissa E. Elraziky, Wafaa A, et al. Safety, Dosage and Efficacy of a Novel Y shaped molecule of Pegylated Interferon alpha 2a for Treatment of Chronic HCV. Accepted poster (AASLD 2011).
25. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int. 2011; 31 (Suppl. 1): 68-77.
26. Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment - finding the right path. Nat Rev Drug Discov 2007; 6: 991-1000.
27. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
28. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
29. Benhamou Y, Moussalli J, Ratziu V, et al. Results of a proof of concept study (C210) of Telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients. J Hepatol 2009; 50: S6.
30. Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 4432-41.
31. Jensen DM, Wedemeyer H, Herring RW, et al. High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12interim analysis from the PROPEL study. Hepatology 2010; 52: (abstract 81).
32. Elazar M, Liu M, McKenna SA, et al. The antihepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology 2009; 137: 1827-35.
33. Rossignol JF, Kabil SM, El Gohary Y, et al. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008; 28: 574-80.
34. Mederacke I, Wedemeyer H. Nitazoxanide for the treatment of chronic hepatitis C New opportunities but new challenges? Ann Hepatol 2009; 8: 166-8.
35. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49: 1460-8.
36. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-7.
37. Beinhardt S, Rasoul-Rockenschaub S, Matthias Scherzer T, et al. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in patient with chronic hepatitis C. J Hepatol 2010; 54: 591-2.
38. Abu-Mouch SM, Fireman Z, Jarchovsky J, et al. The beneficial effect of vitamin D with combined peginterferon and ribavirin for chronic HCV infection. Presented at The Liver Meeting 2009: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): Abstract LB20. November 2, 2009.
39. Qiu D, Lemm JA, O'Boyle DR 2nd, et al. HCV NS5A Inhibitors Modulate Multiple Aspects of NS5A Expression. J Gen Virol 2011; 92: 2502-11.
40. Hézode C, Hirschfield GM, Ghesquiere W, et al. A NS5A replication complex inhibitor, combined with PEG-Interferon-Alpha-2A and ribavirin in treatment-naïve HCV-Genotype 1 or 4 subjects: The phase 2B momentum study week 12 results. Accepted poster (AASLD 2011).
41. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011; in press.